Press Release
-
2026/07/24 ASH
ASH Clinical News | Base Editing Contributes to Meaningful HbF Production in Beta Thalassemia
Both transformer Base Editing (tBE) and CRISPR-Cas9 nuclease-mediated editing can induce precise, targeted base substitutions in human hematopoietic stem cells. tBE has an advantage over CRISPR-Cas9 in that it does not generate DNA double-strand breaks (DSBs), thereby avoiding the consequent p53-mediated stress and apoptosis. This difference has been demonstrated in preclinical studies, which have shown that tBE-modified hematopoietic stem and progenitor cells (HSPCs) exhibit reduced cell-cycle arrest and apoptosis, along with enhanced proliferative capacity compared with Cas9-edited cells.
-
2026/04/24 China Daily
China Daily | Chinese Researchers Debut Breakthrough DNA Repair Tool for Genetic Disorders
A domestically developed gene-editing therapy has successfully treated patients with beta-thalassemia, allowing them to live without the need for lifelong blood transfusions, according to a study published on Wednesday in the journal Nature.
-
2026/04/09 Xinhua Net
In a milestone for genetic medicine, researchers in China have reported the world's first clinical success using a revolutionary "base-editing" technique to treat patients with a severe inherited blood disorder.
-
2025/05/23 China Daily
China Daily | Chinese treatment cures Pakistani girl
A 4-year-old Pakistani girl with severe thalassemia has been successfully treated with a Chinese-developed gene-editing drug, marking the first time the technology has been used on a foreign minor, according to the Children's Hospital of Fudan University in Shanghai.